Current Oncology Reports最新文献

筛选
英文 中文
Correction to: Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis. 更正:替沃扎尼单药治疗转移性肾细胞癌患者的一线治疗和良好预后。
IF 4.7 2区 医学
Current Oncology Reports Pub Date : 2025-06-01 DOI: 10.1007/s11912-025-01670-6
Ricky Frazer, José Ángel Arranz, Sergio Vázquez Estévez, Omi Parikh, Laura-Maria Krabbe, Naveen S Vasudev, Christian Doehn, Norbert Marschner, Tom Waddell, Will Ince, Peter J Goebell
{"title":"Correction to: Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis.","authors":"Ricky Frazer, José Ángel Arranz, Sergio Vázquez Estévez, Omi Parikh, Laura-Maria Krabbe, Naveen S Vasudev, Christian Doehn, Norbert Marschner, Tom Waddell, Will Ince, Peter J Goebell","doi":"10.1007/s11912-025-01670-6","DOIUrl":"10.1007/s11912-025-01670-6","url":null,"abstract":"","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"788-790"},"PeriodicalIF":4.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143996099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rare Genetic and Uncommon Morphological Entities in Adults with Acute Myeloid Leukemia. 成人急性髓性白血病罕见的遗传和不常见的形态学实体。
IF 4.7 2区 医学
Current Oncology Reports Pub Date : 2025-06-01 Epub Date: 2025-04-28 DOI: 10.1007/s11912-025-01678-y
Xavier Thomas
{"title":"Rare Genetic and Uncommon Morphological Entities in Adults with Acute Myeloid Leukemia.","authors":"Xavier Thomas","doi":"10.1007/s11912-025-01678-y","DOIUrl":"10.1007/s11912-025-01678-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>Despite differences in the various classification systems of acute myeloid leukemia (AML), rare entities can be identified according to clinical, biological or morphological characteristics. Uncommon AML defined on specific morphological criteria and/or genetic abnormalities were considered if occurring with a frequency of ≤ 5% in adult patients with AML.</p><p><strong>Recent findings: </strong>Most of uncommon AML are characterized by a poor outcome with the standard treatment approaches. During the last decade, several therapeutic drugs with promising investigational approaches have been used in therapeutic regimens in both frontline and relapsed/refractory AML and represent a positive potential benefit for some rare entities displaying specific molecular lesions. Several rare subtypes can be identified in adult patients with AML. In this descriptive review, we assess the available information for these rare entities and summarized treatments that could be proposed especially according to their genetic characterization.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"734-747"},"PeriodicalIF":4.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute Management of Hypercalcemia of Malignancy - A Review of Pathophysiology, Diagnosis, and Treatment. 恶性肿瘤高钙血症的急性治疗——病理生理学、诊断和治疗综述。
IF 4.7 2区 医学
Current Oncology Reports Pub Date : 2025-05-28 DOI: 10.1007/s11912-025-01685-z
Ashley Crouch, Aysha Chaudhri, Sonya Khan, Maggie Ma, Ngoc Vu, William Towers
{"title":"Acute Management of Hypercalcemia of Malignancy - A Review of Pathophysiology, Diagnosis, and Treatment.","authors":"Ashley Crouch, Aysha Chaudhri, Sonya Khan, Maggie Ma, Ngoc Vu, William Towers","doi":"10.1007/s11912-025-01685-z","DOIUrl":"https://doi.org/10.1007/s11912-025-01685-z","url":null,"abstract":"<p><strong>Purpose of review: </strong>Hypercalcemia of malignancy is one of the most common metabolic disorders in patients with cancer and is associated with significant morbidity and mortality. This narrative review summarizes pathophysiology, clinical presentation, diagnostic strategies, and therapies available for the management of hypercalcemia of malignancy in acutely ill adult patients.</p><p><strong>Recent findings: </strong>We reviewed both classic and recent literature to provide practical recommendations for managing cancer-related hypercalcemia. Our findings are presented in the context of recently published societal guidelines. Timely identification and treatment of acute hypercalcemia of malignancy is vital. Understanding of the underlying disease processes and available therapies is needed to optimize patient care and healthcare resource utilization.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144157208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of Metastatic Hormone Receptor-Positive Breast Cancer Beyond CDK4/6 Inhibitors. 不使用CDK4/6抑制剂治疗转移激素受体阳性乳腺癌
IF 4.7 2区 医学
Current Oncology Reports Pub Date : 2025-05-28 DOI: 10.1007/s11912-025-01689-9
Philip D Tracy, Emily Bopp, Emily Milner, Ana C Garrido-Castro, Antonio Giordano, Erica L Mayer, Sara M Tolaney, Paolo Tarantino, Ilana Schlam
{"title":"Management of Metastatic Hormone Receptor-Positive Breast Cancer Beyond CDK4/6 Inhibitors.","authors":"Philip D Tracy, Emily Bopp, Emily Milner, Ana C Garrido-Castro, Antonio Giordano, Erica L Mayer, Sara M Tolaney, Paolo Tarantino, Ilana Schlam","doi":"10.1007/s11912-025-01689-9","DOIUrl":"https://doi.org/10.1007/s11912-025-01689-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>Since the introduction of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) as the first-line treatment for metastatic hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (HR+/HER2-) breast cancer, there has been a significant expansion in the number of therapeutic options for subsequent lines of therapy. Many new agents are being studied, with potential for future regulatory approval. The increased number of therapeutic options raises questions about the optimal selection and sequencing of therapies for individual patients. These advances represent an important clinical challenge in this rapidly evolving field, given the introduction of new therapies targeting various pathways (alone or in combination) and new therapeutic classes being studied.</p><p><strong>Recent findings: </strong>Recently approved targeted therapies have demonstrated improvements in progression free survival (PFS) for patients whose cancer harbors mutations in the PI3K/AKT pathway, ESR1, BRCA1/2, and/or PALB2. Data to support continuation of CDK4/6 inhibition after progression on a prior CDK4/6i remains mixed, though some studies suggest a subset of patients may benefit from this approach. Several agents with unique mechanisms of action have shown promise in data from early phase trials, and have the potential to enter the treatment lexicon in the coming years. Examples include CDK2- and CDK4-selective inhibitors, complete estrogen receptor antagonists (CERANs), proteolysis targeting chimeras (PROTACs), and next-generation PI3K pathway inhibitors. In this narrative review, we summarize the current and upcoming treatments for metastatic HR+/HER2- breast cancer after progression on a CDK4/6i plus ET, with a focus on the following: an overview of first-line regimens of CDK4/6i plus ET and observed mechanisms of resistance; currently approved second-line therapy options; and upcoming options currently under exploration in clinical trials. We focus primarily on new therapy classes that may offer therapeutic options beyond currently available treatments.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144157209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Management of Metastatic Thymoma and Thymic Carcinoma. 转移性胸腺瘤和胸腺癌的治疗管理。
IF 4.7 2区 医学
Current Oncology Reports Pub Date : 2025-05-28 DOI: 10.1007/s11912-025-01680-4
Nicolas Girard
{"title":"Therapeutic Management of Metastatic Thymoma and Thymic Carcinoma.","authors":"Nicolas Girard","doi":"10.1007/s11912-025-01680-4","DOIUrl":"https://doi.org/10.1007/s11912-025-01680-4","url":null,"abstract":"<p><strong>Purpose of the review: </strong>Assess new options and best sequence or combination strategies for the treatment of metastatic thymic epithelial tumors.</p><p><strong>Recent findings: </strong>Besides historical cytotoxic chemotherapy regimens, which remain standard-of-care for many patients with thymoma, new options include antiangiogenic agents and immune checkpoint inhibitors (ICIs) in the first-line setting combined with carboplatin and paclitaxel for thymic carcinoma. Antiangiogenic agents are also used in the second-line setting, possibly sequenced or combined with ICIs. With the latter, comprehensive assessment for autoimmune disorders is advised, with subsequent close clinical and biological monitoring. Precision medicine strategies may be implemented with comprehensive genomic profiling and use of targeted agents. Multidisciplinary tumor board is key to optimize the treatment pathway for patients with metastatic thymic epithelial tumors, with a need for prospective studies assessing the best combination strategies.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144157211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medical Management of Tenosynovial Giant Cell Tumor. 腱鞘巨细胞瘤的医学处理。
IF 4.7 2区 医学
Current Oncology Reports Pub Date : 2025-05-20 DOI: 10.1007/s11912-025-01679-x
Emanuela Palmerini, Jonathan C Trent, Francis John Hornicek
{"title":"Medical Management of Tenosynovial Giant Cell Tumor.","authors":"Emanuela Palmerini, Jonathan C Trent, Francis John Hornicek","doi":"10.1007/s11912-025-01679-x","DOIUrl":"https://doi.org/10.1007/s11912-025-01679-x","url":null,"abstract":"<p><strong>Purpose of review: </strong>Diffuse tenosynovial giant cell tumor (D-TGCT) is a benign neoplasm with locally aggressive potential of the synovium, bursae, and tendon sheaths. This review summarizes the current treatment landscape for D-TGCT, with a focus on systemic therapies.</p><p><strong>Recent findings: </strong>Surgery is the primary treatment option for tenosynovial giant cell tumor (TGCT), but there is a high risk of recurrence and associated morbidity, particularly for patients with advanced D-TGCT. Systemic therapies targeting the colony-stimulating factor 1 receptor (CSF1R) have resulted in positive tumor response, improved function, and decreased symptoms. For an alternative to surgery, the CSF1R inhibitors pexidartinib and vimseltinib are approved in the United States for TGCT, and other CSF1R inhibitors are in clinical development. CSF1R inhibitors represent a significant evolution in therapeutic strategies for D-TGCT. The potential risks and benefits of available treatments should be carefully considered in collaboration with a bone tumor-experienced, multidisciplinary team to determine the best course of care. Increased D-TGCT awareness and support through patient advocacy groups have helped to reshape the patient journey.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Imiquimod for Anal High Grade Intraepithelial Neoplasia: A Systematic Review. 咪喹莫特治疗肛门高级别上皮内瘤变:系统综述。
IF 4.7 2区 医学
Current Oncology Reports Pub Date : 2025-05-19 DOI: 10.1007/s11912-025-01675-1
Niccolò Gallio, Mario Preti, Elena Casetta, Andreia Albuquerque, Pedro Vieira-Baptista, Fulvio Borella, Federica Bevilacqua, Camilla Cavallero, Massimiliano Mistrangelo, Alberto Revelli
{"title":"Imiquimod for Anal High Grade Intraepithelial Neoplasia: A Systematic Review.","authors":"Niccolò Gallio, Mario Preti, Elena Casetta, Andreia Albuquerque, Pedro Vieira-Baptista, Fulvio Borella, Federica Bevilacqua, Camilla Cavallero, Massimiliano Mistrangelo, Alberto Revelli","doi":"10.1007/s11912-025-01675-1","DOIUrl":"https://doi.org/10.1007/s11912-025-01675-1","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to investigate the efficacy of imiquimod in Anal High Grade Squamous Intraepithelial Lesion (HSIL).</p><p><strong>Methods: </strong>Electronic databases (Pubmed, MEDLINE, EMBASE and Cochrane Library databases) were searched from inception until December 2024 for articles reporting imiquimod as a treatment for anal HSIL.</p><p><strong>Results: </strong>Five studies were identified (2 randomized controlled trials and 3 prospective non-randomized studies), containing data on 126 men of have sex with men living with HIV with anal HSIL. Most studies contained significant bias which prevented direct comparison. Reported complete response (CR) rates ranged between 14.3-78.6%, and 21.4-67% partial response (PR) rates of 3-weekly application for 16 weeks imiquimod course. A second course of imiquimod led to incremental response (CR 15-23.8%, PR 19-30%). Perianal HSIL showed superior response rates compared to intra-anal lesions (perianal HSIL CR ranging from 71.4 to 100%, intra-anal HSIL CR from 10.8 to 33.3%).</p><p><strong>Discussion: </strong>In our systematic review we summarized the literature regarding imiquimod use for anal HSIL treatment, both perianal/intra-anal. Imiquimod can be proposed as a safe treatment of anal HSIL, and perianal HSIL may benefit more from imiquimod treatment. However, anal HSIL recurrence rates were high, and there are no long-term data on its efficacy. No studies investigated the role of imiquimod in women or in HIV- patients.</p><p><strong>Conclusion: </strong>Imiquimod can be proposed as a safe option for treatment of anal HSIL.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
State-of-the-art in Metastatic Uveal Melanoma Treatment: A 2025 Update : How to treat Metastatic Uveal Melanoma in 2025. 转移性葡萄膜黑色素瘤治疗的最新进展:2025年最新进展:2025年如何治疗转移性葡萄膜黑色素瘤。
IF 4.7 2区 医学
Current Oncology Reports Pub Date : 2025-05-17 DOI: 10.1007/s11912-025-01684-0
Dimitrios C Ziogas, Dimitra Foteinou, Charalampos Theocharopoulos, Anastasios Martinos, Dioni-Pinelopi Petsiou, Amalia Anastasopoulou, Helen Gogas
{"title":"State-of-the-art in Metastatic Uveal Melanoma Treatment: A 2025 Update : How to treat Metastatic Uveal Melanoma in 2025.","authors":"Dimitrios C Ziogas, Dimitra Foteinou, Charalampos Theocharopoulos, Anastasios Martinos, Dioni-Pinelopi Petsiou, Amalia Anastasopoulou, Helen Gogas","doi":"10.1007/s11912-025-01684-0","DOIUrl":"https://doi.org/10.1007/s11912-025-01684-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>Uveal melanoma (UM) is the most common intraocular malignancy in adults, representing a rare but aggressive melanoma subtype with a distinct molecular landscape, unique metastatic behavior and limited therapeutic options in the metastatic setting. This review provides an in-depth analysis of the latest evidence on the evolving treatment landscape of metastatic UM.</p><p><strong>Recent findings: </strong>For liver-only metastatic disease, locoregional therapies provide significant benefit compared to systemic therapies. The recent approval of tebentafusp-tebn, a bispecific gp100 peptide-HLA-directed CD3 T-cell engager, marks a pivotal advancement for HLA-A*02:01-positive patients with unresectable/metastatic UM, demonstrating a clinically significant survival benefit. Several clinical studies are currently active, examining emerging locoregional and systemic treatments for metastatic UM, with promising early data. Despite effective local disease control through radiotherapy and enucleation, approximately 50% of patients develop metastatic disease, predominantly in the liver, with a median survival of less than one year. The approval of tebentafusp represents a landmark achievement in UM treatment, while promising experimental combinations have demonstrated clinical utility in late phase clinical trials, offering hope for further improvement in patient survival.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant or Adjuvant Chemotherapy in Soft-Tissue Sarcoma? 软组织肉瘤的新辅助还是辅助化疗?
IF 4.7 2区 医学
Current Oncology Reports Pub Date : 2025-05-01 Epub Date: 2025-01-05 DOI: 10.1007/s11912-024-01630-6
Piotr Remiszewski, Kinga Filipek, Agata Pisklak, Paulina Chmiel, Piotr Rutkowski, Anna M Czarnecka
{"title":"Neoadjuvant or Adjuvant Chemotherapy in Soft-Tissue Sarcoma?","authors":"Piotr Remiszewski, Kinga Filipek, Agata Pisklak, Paulina Chmiel, Piotr Rutkowski, Anna M Czarnecka","doi":"10.1007/s11912-024-01630-6","DOIUrl":"10.1007/s11912-024-01630-6","url":null,"abstract":"<p><strong>Purpose of review: </strong>The review compares the effectiveness of neoadjuvant(pre-operative, NAC) and adjuvant(post-operative, AC) in Soft Tissue Sarcomas as this topic is controvesial and multiple new studies have been over the years.</p><p><strong>Recent findings: </strong>Sarculator and other nomograms assess patients with a predicted 10-year OS below 60% who will benefit from perioperative chemotherapy. Further research supports perioperative chemotherapy's role. European guidelines do not recommend anthracycline and ifosfamide (AI) perioperative chemotherapy as a standard treatment for STS of the extremities and trunk. However, some studies show that AI chemotherapy can improve recurrence-free survival (RFS). The EORTC 62,771 trial found that the CYVADIC regimen (doxorubicin, dacarbazine, cyclophosphamide, vincristine) reduced RFS without affecting OS. Meanwhile, the EORTC 62,931 trial showed no effect of AI chemotherapy on RFS or OS, but a pooled analysis suggested an OS benefit for patients with R1 (microscopically positive) resections. The AI regimen shows further support from Sarculator-based data, with EORTC 62,931 analysis indicating an improvement in disease-free survival and OS in patients with low expected OS. Similar outcomes were seen in the ISG-STS 1001 study. Recently, PERSARC analysis revealed that AI chemotherapy significantly improves OS in high-grade STS patients with a low 5-year OS prediction (< 33%). NAC improves the chances of complete tumour removal, especially in large, high-grade tumours. It often reduces the need for more aggressive surgeries by shrinking tumours before surgery, leading to higher rates of successful resections with clear margins (R0). Sarculator and other nomograms assess patients with a predicted 10-year OS below 60% who will benefit from perioperative chemotherapy. Further research supports perioperative chemotherapy's role.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"491-515"},"PeriodicalIF":4.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mesenteric Fibrosis in Neuroendocrine Neoplasms: a Systematic Review of New Thoughts on Causation and Potential Treatments. 神经内分泌肿瘤的肠系膜纤维化:病因和潜在治疗新思路的系统综述。
IF 4.7 2区 医学
Current Oncology Reports Pub Date : 2025-05-01 Epub Date: 2025-04-11 DOI: 10.1007/s11912-025-01668-0
Ariadni Spyroglou, Odysseas Violetis, Konstantinos Iliakopoulos, Antonios Vezakis, Krystallenia Alexandraki
{"title":"Mesenteric Fibrosis in Neuroendocrine Neoplasms: a Systematic Review of New Thoughts on Causation and Potential Treatments.","authors":"Ariadni Spyroglou, Odysseas Violetis, Konstantinos Iliakopoulos, Antonios Vezakis, Krystallenia Alexandraki","doi":"10.1007/s11912-025-01668-0","DOIUrl":"10.1007/s11912-025-01668-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>Mesenteric fibrosis (MF) is a hallmark of small intestinal neuroendocrine neoplasms (SI-NEN) and is frequently associated with significant morbidity due to related complications such as intestinal obstruction, ischemia, and cachexia.</p><p><strong>Recent findings: </strong>Herein we performed a systematic review to discuss the development of MF in SI-NEN. The pathophysiological mechanisms acknowledged as causative for the development of MF include the major components of the tumor microenvironment, such as fibroblasts, endothelial and immune cells and the extracellular matrix, which are involved in a complex interplay activating several signaling pathways that promote profibrotic factors and induce both a desmoplastic reaction and tumor proliferation. Surgery remains the mainstay of treatment, while several medical management options of MF complicating SI-NEN available present rather limited efficacy. MF is a frequent characteristic of SI-NEN that requires particular attention and targeted management to avoid complications.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"642-655"},"PeriodicalIF":4.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信